Surge2Surgery raises $2.6M and secures exclusive license agreement

Surge2Surgery raises $2.6M and secures exclusive license agreement

Surge, a biotechnology and artificial intelligence innovator producing technology to decode immune fingerprints, received $2.6 million in funding.

The technology accurately identifies at-risk patients before surgery and allows doctors to quickly predict the risk of postoperative complications.

The funding round was co-led by HCVC, a global seed fund dedicated to high-potential tech startups, and Boutique Venture Partners, a leading Silicon Valley-based fund. Veteran angel investors, including Nicolas Godin, the COO/CFO of Cardiologs, also participated in the round. Surge received the 2022 iLab grant, as well as other non-dilutive grants to supplement fundraising.

Machine learning algorithms

Hosted in the US by StartX, a community of non-profit founders, as well as supported in Europe by Agoranov, 50 Partners and Wilco, Surge’s flagship product uses innovative machine learning algorithms to decode the immune system of a patient from a blood sample.

Julien Hédou, president and co-founder of Surge, said: “Our ambition is to develop the reference solution for precision surgical medicine. We plan to expand and diversify the applications of our technology with immune profiling tools for all surgical complications. Eventually, we also want to apply our methodology to other therapeutic areas.

With 30% of major surgeries currently resulting in complications and 40% of patients aged 65+ suffering lasting cognitive impacts following orthopedic or cardiac surgery, Surge’s solution enables targeted and personalized interventions to reduce the risk of complications. post-surgery in patients.

A patented solution

The technology combines a biological analysis of the immune system with an AI algorithm, allowing it to calculate each patient’s risk of surgical complications and offer personalized preventive management strategies to optimize the care pathway.

Surge has obtained from Stanford University the exclusive license of the patented technology for predicting postoperative complications developed thanks to more than ten years of research on the prediction of surgical risks led by Brice Gaudillière, physician-researcher and associate professor of anesthesiology , Perioperative and Pain Medicine at Stanford University School of Medicine.

In the summer of 2022, Surge also signed a research agreement with Stanford with the aim of developing biotechnology innovations.

Surgical site infections

The funding round will allow the company to further develop its team and conduct clinical studies with other hospitals, such as the one started in the spring of 2022 with the Foch hospital in Suresnes, France. The Foch study, launched in the spring of 2022, will validate Surge’s prediction on surgical site infections in abdominal surgery.

Alexis Houssou, Founder of HCVC Partners, said: “We are proud to support Surge in its ambition to reduce the risk of postoperative complications. Its international and multidisciplinary team inspires respect. They have created very strong relationships spanning both the French and American academic worlds, with partners such as AP-HP, Institut Pasteur and Stanford, building a strong network that will allow them to achieve their goals.

Of the nearly 6.1 million and 5.1 million abdominal surgeries performed annually in the United States and Europe respectively, approximately 30% result in postoperative complications such as infections, cognitive decline, or thromboembolic events.

Burden of Complications

Transparency Market Research reports that these complications typically require additional care or rehospitalization, resulting in high healthcare costs and patient morbidity and mortality. The burden of complications increases as the population ages and the number of surgeries increases by almost 5% per year.

Rami El Assal, co-founder of Boutique Venture Partners, said, “We are excited to partner with the Surge team to help decode immune fingerprinting to accurately identify at-risk patients prior to surgery. What impresses us most about Surge is the ability to integrate a proprietary machine learning algorithm with single-cell and plasma proteomics data to predict surgical complications, including infection and cognitive decline.

“We were familiar with Dr. Gaudillière’s work at Stanford, even before we met him, and his approach of using the power of single-cell mass cytometry to identify immune dysfunction underlying pathological stressors.”

Similar Posts

Leave a Reply

Your email address will not be published.